Ribociclib-induced hepatotoxicity.
J Oncol Pharm Pract
; 29(5): 1275-1277, 2023 Jul.
Article
en En
| MEDLINE
| ID: mdl-36762416
ABSTRACT
INTRODUCTION:
Cyclin-dependent kinase (CDK) 4/6 inhibitors have shown a different adverse effect. In this case, persistent grade 3 hepatoxicity was observed after ribociclib. Therefore, ribociclib therapy was stopped, and then palbociclib was introduced. Transaminase levels returned to normal by switching to palbociclib therapy. CASE REPORT 71-year-old postmenopausal female patient with luminal subtypes of metastatic breast cancer treated with ribociclib. MANAGEMENT &OUTCOME:
Grade 3 hepatotoxicity secondary to ribociclib developed. She was successfully treated with palbociclib 125â mg.DISCUSSION:
In our case, palbociclib was started with a full dose, to increase treatment success. Starting with a 125â mg dose was not cause any toxicity. Nevertheless, laboratory follow-up is required in terms of neutropenia and increased transaminases.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos
/
Enfermedad Hepática Inducida por Sustancias y Drogas
Tipo de estudio:
Etiology_studies
Límite:
Aged
/
Female
/
Humans
Idioma:
En
Año:
2023
Tipo del documento:
Article